Barclays lowered the firm’s price target on Exact Sciences (EXAS) to $55 from $65 and keeps an Overweight rating on the shares following the earnings report. The firm says not a lot changed in blood-based screening market dynamics over the long term.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXAS:
- Exact Sciences Corp. Reports Strong Q2 2025 Results
- Closing Bell Movers: DoorDash jumps 8%, Airbnb slips 6% on earnings
- Exact Sciences Announces Collaboration with Freenome Holdings
- Exact Sciences raises 2025 revenue outlook $3.13B-$3.17B
- Exact Sciences acquires Freenome colorectal cancer screening tests